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PROX1 is a transcription factor involved in the development of various organs. It has also an
important function in colorectal cancer progression. The aim of this study was to investigate
the prognostic role of PROX1 expression in gastric cancer.
Methods
We evaluated PROX1 expression in gastric cancer by immunohistochemistry of tumor-tis-
sue microarrays including tumor specimens from 283 patients who underwent surgery at
Helsinki University Hospital. We investigated the association of PROX1 expression with
clinicopathologic variables and patient survival.
Results
Cytoplasmic PROX1 reactivity was high in 56 (20.5%) and low in 217 (79.5%) cases. Low
PROX1 immunostaining associated with diffuse cancer type (p = 0.002). In subgroup analy-
sis, PROX1 was a significant marker of better prognosis in patients aged under 66 (p =
0.007), in those with intestinal cancer (p = 0.025), among men (p = 0.019), and in tumors of
less than 5 cm diameter (p = 0.030). Patients with high PROX1 expression had a cancer-
specific 5-year survival of 65.6% (95% CI 52.7–78.5), compared to 37.1% (95% CI 30.2–
44.0) for those with low expression (p = 0.004, log-rank test). This result remained significant
in multivariable analysis (HR = 0.56; 95% CI 0.35–0.90; p = 0.017).
Conclusion
In gastric cancer, high cytoplasmic PROX1 expression is an independent marker of better
prognosis.
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Introduction
Gastric cancer is a highly malignant tumor and is globally one of the major causes of cancer-
related death [1]. Its incidence in the last decades has decreased, but its 5-year survival rate,
despite curative surgery is, in the Western world, still less than 30% [2]. Besides the established
prognostic factors such as TNM-stage together with the possibility of curative surgery, addi-
tional prognostic information may come from tumor markers.
The transcription factor PROX1 is a key regulatory protein in the development of various
organs. It is involved in cell-fate determination and progenitor-cell regulation in the central
nervous system, eye, liver, pancreas, lymphatic system, and the heart. It also plays a role in can-
cer development. Previous studies have indicated that PROX1 can have either tumor-suppres-
sive or oncogenic properties. Various levels of PROX1 protein occur in tumor cells, but the
role of PROX1 in the proliferation, migration, and invasion of cancer cells is unclear [3].
PROX1 is involved in various gastrointestinal tract tumors [4–10], in hematological malig-
nancies [11], in breast cancer [12], in Kaposi sarcoma [13], and in brain tumors [14,15]. In
colorectal cancer, PROX1 plays an essential role in tumor progression; high immunohisto-
chemical nuclear PROX1 expression is associated with poor patient outcome [4,5]. Conversely,
in hepatocellular carcinomas [6], in pancreatic ductal adenocarcinomas [8,9], and in carcino-
mas of the biliary system [10], low PROX1 expression is associated with poor prognosis. In
esophageal squamous cell carcinoma cells, over-expression of PROX1 inhibits tumor cell pro-
liferation [7].
In gastric cancer, PROX1 may promote tumor progression by inducing cancer-cell prolifer-
ation and lymphangiogenesis [16]. PROX1 expression when, appearing in gastric cancer tissue,
may serve as a potential prognostic factor and treatment target. Moreover, tumorigenesis and
tumor progression is also linked to dysregulation of microRNAs. Recently Zhang et al. [17]
found that miR-489 was significantly downregulated in human gastric cancer tissues and cell
lines, and PROX1 was a direct miR-489 target.
The aim of this study was to determine the prognostic value of immunohistochemical stain-
ing of PROX1 in gastric cancer.
Materials and methods
Patients
In total, 313 patients underwent surgery for histologically verified gastric adenocarcinoma at
the Department of Surgery, Helsinki University Hospital between 2000 and 2009. We included
283 tissue samples from patients undergoing total or partial gastrectomy with D1- or D2-lym-
phadenectomy, 228 (72.8%) of them with curative intent, whereas 85 (27.2%) underwent palli-
ative surgery. Median age was 67.4 (interquartile range 57.1–76.5); 161 (51.4%) were women.
Stage distribution according to the 7th edition of the UICC classification was 62 (19.9%) stage
IA-IB, 72 (23.1%) stage IIA-IIB, 115 (36.8%) stage IIIA-IIIC, and 63 (20.2%) stage IV patients.
Lymph-node metastases occurred in 198 (65.6%) and distant metastases in 63 (20.1%). Of the
313 patients, 15 (4.8%) received neoadjuvant treatment, and 125 (39.9%) postoperative adju-
vant treatment (74 chemotherapy, 2 radiotherapy, and 50, both). Survival data and causes of
death until October 2016 came from patient records, the Population Register Centre of Fin-
land, and Statistics Finland.
The study was approved by the Surgical Ethics Committee of Helsinki University Hospital
(Dnro HUS 226/E6/ 06, extension TMK02 §66 17.4.2013) and the National Supervisory
Authority of Welfare and Health gave permission to use the tissue samples without individual
consent in this retrospective study (Valvira Dnro 10041/06.01.03.01/2012).
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Tissue samples and immunohistochemistry
We collected formalin-fixed and paraffin-embedded surgical tissue samples from the archives
of the Department of Pathology, and de-identified and analyzed the tissue samples anony-
mously. All histological slides were re-evaluated by an experienced pathologist who defined
and marked areas representing the highest grade of the individual tumor. Four 1.0-mm cores
from each tumor block, two from the invasive front, and two from the center of the tumor,
were sampled and embedded in a new paraffin block by a semi-automatic tissue microarrayer
(Tissue Arrayer 1, Beecher Instruments Inc., Silver Spring, MD, USA) as previously described
[18]. Sections of 4 μm were cut and processed for immunohistochemistry.
Sections were fixed on slides and dried for 12 to 24 hours at 37˚C, then they were deparaffi-
nized in xylene and rehydrated through gradually decreasing concentrations of ethanol to dis-
tilled water. For antigen retrieval, sections were treated in a PreTreatment module (Lab Vision
Corp., Fremont, CA, USA) in Tris-HCl (pH 8.5) and in Tris-EDTA (pH 9) buffer for 20 min-
utes at 98˚C. Sections were stained in an Autostainer 480 (Lab Vision). Tissues were incubated
with anti-human Prox1 Antibody (R&D Systems, Inc., Minneapolis, MN, USA; diluted to
1:1800 = 18 μg/ml) overnight at room temperature. For detection ImmPRESS HRP Polymer
Detection Kit, Peroxidase, anti-goat IgG (Vector Laboratories, Burlingame, CA, USA) was
used. Colon cancer tissue served as a positive control for staining.
Scoring of immunoreactivity
PROX1 immunoreactivity was successfully scored in 273 tumors. We scored cytoplasmic
PROX1 intensity in cancer cells as 0 to 3. Negative immunoreactivity was scored as 0, weak
positivity 1, moderate positivity 2, and strong positivity 3. All samples were scored indepen-
dently by two researchers (A.L. and J.H.) without knowledge of clinical status and outcome
data. Samples with discordant scores were re-evaluated until consensus was reached. The high-
est score of the four cores served for further analysis.
Statistical analyses
Associations between PROX1 positivity and clinicopathological variables were assessed by the
chi-square test or Fisher’s exact test. Disease-specific survival was calculated from date of sur-
gery to death from gastric cancer.
Survival curves were constructed according to the Kaplan-Meier method and compared
with the log-rank test. For univariable and multivariable survival analysis, the Cox propor-
tional hazard model had the following covariates entered: age, gender, stage, TNM classifica-
tion, Lauréns classification, tumor size, and PROX1 expression. Stage, TNM classification, and
tumor size were categorical covariates. A p-value of<0.05 was consider statistically significant.
All statistical analyses were done with IBM SPSS Statistics version 22.0 (IBM Corporation,
Armonk, NY, USA).
Results
Immunohistochemistry and association of PROX1 with
clinicopathological variables
Of 273 cases, the cytoplasmic PROX1 reactivity was weakly positive in 99 (36.3%), moderately
positive in 39 (14.3%), strongly positive in 17 (6.2%), and negative in 118 (43.2%). In the final
analysis, negative and weakly positive was regarded as low expression, and moderately and
strongly positive as high expression. Representative images of immunostainings are presented
in Fig 1. PROX1 staining occurred mainly in the cytoplasm, and in some strongly stained
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samples we noted also nuclear immunopositivity. Low PROX1 immunostaining associated
with diffuse cancer type (p = 0.002; Table 1). No other clinicopathological variables associated
with PROX1.
Survival analyses
In gastric cancer-specific survival analysis according to the Kaplan-Meier method patients
with strong and the moderate immunostaining have clearly better survival than patients with
weak or negative immunoexpression (p = 0.033, log-rank test; Fig 2A). In the final analysis, we
combined strong and moderate immunoexpression to represent high expression and weak
and negative immunoexpression to represent low expression. Gastric cancer patients with
high PROX1 expression had a cancer-specific 5-year survival of 65.6% (95% CI 52.7–78.5),
compared to 37.1% (95% CI 30.2–44.0) for patients with low expression (p = 0.004, log-rank
test; HR = 0.52 (95% CI 0.33–0.82), Fig 2B, Table 2).
In subgroup analysis, PROX1 was a significant marker of better prognosis in patients aged
under 66 (p = 0.007), among men (p = 0.019), and among patients with tumors of less than 5
cm in diameter (p = 0.030). PROX1 was a significant marker of better prognosis in the sub-
group of intestinal cancer type (p = 0.025; Fig 3A) whereas it did not show a prognostic signifi-
cance among patients with diffuse cancer type (p = 0.290; Fig 3B). In other subgroups studied
PROX1 did not serve as a prognostic marker.
PROX1 expression remained significant in multivariable analysis (HR = 0.56; 95% CI 0.35–
0.90; p = 0.017; Table 3). Other independent prognostic factors in multivariable analysis were
advanced age and distant metastasis, and tumor size greater than 5 cm.
Discussion
Here we show that cancer-specific 5-year survival was significantly better for gastric cancer
patients with PROX1-positive tumors. In multivariable analysis, high PROX1 immunopositiv-
ity served as an independent marker of better prognosis. Among patients with intestinal can-
cer, those with high PROX1 immunostaining had superior survival.
PROX1 was expressed evenly throughout the cytoplasm, and in some strongly stained sam-
ples we noted also nuclear positivity. Earlier studies have reported both cytoplasmic and
nuclear staining patterns [16,19]. The cytoplasmic PROX1 expression by immunohistochemis-
try correlates with PROX1 mRNA amplification [19]. High mRNA levels correlate also with
regional lymph node metastasis but not with distant metastasis. Depending on the cancer, the
Fig 1. Representative images of PROX1 staining representing gastric cancer tumors with negative (A), weak (B), moderate
(C), and strong (D) staining. Original magnification 40x.
https://doi.org/10.1371/journal.pone.0183868.g001
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staining pattern varies. In colonic [4] and hepatocellular carcinomas [6] and in gliomas [15],
the PROX1 staining is mainly nuclear, whereas in pancreatic cancer, mainly cytoplasmic stain-
ing is observed [9]. The role of cytoplasmic PROX1 expression still remains unknown. One
hypothesis is that PROX1 is enriched and activated in the cytoplasm of the cell before being
translocated to the nucleus to become functionally active [4].
In gastric cancer, Park et al. [16] studied PROX1 by silencing its expression in cell lines by
small interfering RNA against PROX1. Cell proliferation was inhibited by PROX1 knockdown,
suggesting that PROX1 may play a role in regulating cell fate by reducing apoptosis as well as
by promoting proliferation of gastric cancer cells. They also investigated the prognostic role of
PROX1 in 327 gastric cancer patients by immunohistochemistry, finding that the survival of
patients with PROX1-positive tumors was significantly worse than for those with PROX1-ne-
gative tumors. Unexpectedly, our result contradicted this. Reasons for the difference between
their results and the present ones may be several. That 2017 Korean study did not include
patients with metastasis. Our chosen antibody was anti-human Prox1 Antibody (R&D Systems
Table 1. Association of PROX1 with clinicopathological variables in gastric cancer patients.
PROX1
Low High
Clinicopathological variable n n % n % p-value
Age, years
<66 129 104 80.6 25 19.4 0.661
66 144 113 78.5 31 21.5
Gender
Male 130 100 76.9 30 23.1 0.317
Female 143 117 81.8 26 18.2
TNM stage
IA-IB 52 40 76.9 12 23.1 0.375
IIA-IIB 64 47 73.4 17 26.6
IIIA-IIIC 100 81 81.0 19 19.0
IV 56 48 85.7 8 14.3
pT classification
pT1 40 30 75.0 10 25.0 0.706
pT2 40 30 75.0 10 25.0
pT3 85 69 81.2 16 18.8
pT4 108 88 81.5 20 18.5
pN classification
pN0 90 66 73.3 24 26.7 0.246
pN1 37 28 75.7 9 24.3
pN2 62 52 83.9 10 16.1
pN3 76 64 84.2 12 15.8
pM classification
pM0 217 169 77.9 48 22.1 0.196
pM1 56 48 85.7 8 14.3
Laurén classification
Intestinal 111 77 69.4 34 30.6 0.002
Diffuse 154 134 87.0 20 13.0
Tumor size, cm
<5 cm 99 73 73.7 26 26.3 0.109
5 cm 167 137 82.0 30 18.0
https://doi.org/10.1371/journal.pone.0183868.t001
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Fig 2. Gastric cancer-specific survival according to the Kaplan-Meier method, (A) cytoplasmic PROX1 immunoexpression and (B) grouped into
high (strong and moderate staining) and low (weak and negative staining) expression. P-value for log-rank test.
https://doi.org/10.1371/journal.pone.0183868.g002
Table 2. Kaplan-Meier analysis for disease-specific survival stratified for subgroups of gastric cancer patients.
5-year cumulative survival (95% CI)
Subgroup All patients PROX1 low PROX1 high p-value
PROX1 43.3 (37.4–49.2) 37.1 (30.2–44.0) 65.6 (52.7–78.5) 0.004
Age, years
<66 47.8 (39.6–56.0) 42.3 (32.5–52.1) 79.3 (63.0–95.6) 0.007
66 39.1 (31.1–47.1) 32.0 (22.6–41.4) 53.3 (34.5–72.1) 0.140
Gender
Male 46.3 (37.7–54.9) 35.5 (25.1–45.9) 68.5 (51.4–85.6) 0.019
Female 40.9 (33.1–48.7) 38.1 (29.1–47.1) 62.1 (42.5–81.7) 0.095
Laurén classification
Intestinal 52.0 (42.6–61.4) 40.0 (28.2–51.8) 73.7 (57.8–89.6) 0.025
Diffuse 36.7 (29.4–44.0) 35.7 (27.3–44.1) 50.0 (28.0–72.0) 0.290
TNM stage
IA-IB 93.0 (86.3–99.7) 91.9 (83.1–100) 100 0.264
IIA-IIB 64.5 (52.5–76.5) 56.0 (40.7–71.3) 93.8 (81.8–100) 0.041
IIIA-IIIC 23.6 (15.4–31.8) 19.2 (10.2–28.2) 36.5 (13.2–59.8) 0.144
IV 5.7 (0–12.0) 2.4 (0–6.9) 25.0 (0–55.0) 0.745
pT classification
pT1 93.6 (86.5–100) 93.2 (84.2–100) 100 0.275
pT2 77.1 (63.8–90.4) 81.0 (65.9–96.1) 75.0 (44.0–100) 0.789
pT3 32.5 (22.7–42.3) 26.0 (15.4–36.6) 71.4 (47.7–95.1) 0.029
pT4 18.1 (10.7–25.5) 9.9 (3.0–16.7) 40.0 (18.4–61.6) 0.067
pN classification
pN0 73.8 (65.0–82.6) 67.2 (55.4–79.0) 91.5 (80.1–100) 0.169
pN1 45.0 (28.7–61.3) 35.0 (15.8–54.2) 77.8 (50.6–100) 0.081
pN2 36.3 (24.3–48.3) 32.5 (18.8–46.2) 66.7 (35.9–97.5) 0.092
pN3 15.8 (7.6–24.0) 13.9 (5.1–22.7) 16.7 (0–37.9) 0.957
Tumor size, diameter
<5 cm 70.6 (62.0–79.2) 67.1 (56.1–78.1) 87.1 (73.4–100) 0.030
5 cm 25.6 (18.9–32.3) 20.0 (12.7–27.3) 47.9 (29.5–66.3) 0.111
CI = confidence interval
https://doi.org/10.1371/journal.pone.0183868.t002
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Inc.), whereas they used a polyclonal rabbit anti-human PROX1 (Santa Cruz Biotechnology).
They apparently stained whole tissue sections, whereas we utilized the TMA technique. As we
scored cytoplasmic intensity in hot-spot tumor areas, they multiplied the stained area by the
intensity score, and attributed a score more than or equal to 6 out of 9 for positive grouping.
The effects of PROX1 expression on patient prognosis need to be further studied to determine
its value as a prognostic tumor marker.
MicroRNAs (miRNAs) are involved in a variety of biological processes, and their dysregula-
tion is linked to tumorigenesis and tumor progression. Earlier studies suggest an important
role in tumor biology for miR-489. Zhang et al. [17] studied the expression levels of miR-489
in gastric cancer tissues and cell lines to investigate its role in the regulation of aggressive
behavior of gastric cancer cells. They demonstrated that miR-489 is downregulated in human
gastric cancer tissues and cell lines. Interestingly, miR-489 transfection reduces PROX1 pro-
tein in gastric cancer cells, and PROX1 silencing seems to inhibit proliferation. Further,
PROX1 overexpression reverses miR-489-mediated suppression of proliferation and invasion
of gastric cancer cells. In gastric cancer tissues, this study found a negative correlation between
miR-489 and PROX1 protein expression. Zhang et al. suggest that PROX1 is a direct target of
miR-489 in gastric cancer cells. As PROX1 depletion suppresses proliferation, one would
expect that low PROX1 expression would correlate with better survival. In contrast, we noted
the opposite result, because gastric cancer patients with high PROX1 expression had a better
survival than did those with low or no expression.
Petrova et al. [5] in 2008 demonstrated similar findings in colon cancer. According to this
study, PROX1 facilitates tumor progression by affecting cell adhesion and polarity. As a down-
stream effector of TCF/β-catenin signaling in colorectal cancer, loss of PROX1 does not
directly affect cell proliferation, but it rather shifts the transcriptional phenotype of colon can-
cer cells towards more slowly growing adherent cells. Further, overexpression of PROX1
potentiates intestinal adenoma development, suggesting its important role in formation and
growth of in situ lesions, which may progress to carcinoma. In addition to this oncogenic role
of PROX1, it may in gastric cancer play several roles, as we found that high PROX1 expression
was associated with a better prognosis.
The strength of this study is its large gastric cancer patient cohort with a long and reliable
clinical follow-up and survival data. By the TMA method, only small areas of each tumor are
evaluated, not whole-tissue sections. On the other hand, the TMA technique allows analysis of
large patient cohorts with a homogenous staining method.
Fig 3. Expression of PROX1 in the subgroups of (A) intestinal and (B) diffuse cancer type in gastric cancer. P-value for log-rank test.
https://doi.org/10.1371/journal.pone.0183868.g003
High PROX1 expression in gastric cancer predicts better survival
PLOS ONE | https://doi.org/10.1371/journal.pone.0183868 August 30, 2017 7 / 10
In conclusion, our study shows that PROX1 expression serves as a marker of favorable
prognosis in gastric cancer.
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Table 3. Cox regression analysis for disease-specific survival of gastric cancer patients.
Univariable survival analysis Multivariable survival analysis
Variable Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age, years
<66 1.00 1.00
66 1.38 1.02–1.84 0.034 2.45 1.69–3.57 <0.001
Gender
Male 1.00 1.00
Female 1.12 0.83–1.50 0.450 1.16 0.81–1.66 0.406
TNM stage
IA-IB 1.00 1.00
IIA-IIB 5.45 2.26–13.2 <0.001 3.22 0.82–12.6 0.093
IIIA-IIIC 15.7 6.83–35.9 <0.001 8.94 1.84–43.5 0.007
IV 46.1 19.6–109 <0.001 26.9 5.25–138 <0.001
pT classification
pT1 1.00 1.00
pT2 3.38 1.20–9.47 0.021 1.30 0.33–5.09 0.712
pT3 11.9 4.80–29.7 <0.001 1.89 0.44–8.06 0.392
pT4 19.0 7.71–47.0 <0.001 1.90 0.43–8.41 0.401
pN classification
pN0 1.00 1.00
pN1 2.43 1.41–4.20 0.001 0.87 0.44–1.74 0.701
pN2 3.20 2.02–5.09 <0.001 0.69 0.34–1.37 0.283
pN3 6.66 4.32–10.3 <0.001 1.19 0.60–2.35 0.615
pM classification
pM0 1.00 1.00
pM1 5.75 4.11–8.03 <0.001 26.9 5.25–138 <0.001
Laurén classification
Intestinal 1.00 1.00
Diffuse 1.24 0.96–1.61 0.101 1.31 0.94–1.84 0.113
Tumor size
5 cm 1.00 1.00
>5 cm 3.71 2.59–5.33 <0.001 1.64 1.05–2.56 0.030
PROX1
Low 1.00 1.00
High 0.52 0.33–0.82 0.005 0.56 0.35–0.90 0.017
CI = confidence interval
https://doi.org/10.1371/journal.pone.0183868.t003
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